{"preliminary_commentary":{"by_channel":{"x_thread":3},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build."},"free_build":{"available":false},"name":"KANDLELIT-007","nct_id":"NCT07190248","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=kandlelit-007-nct07190248. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"Participants will receive pembrolizumab (+) berahyaluronidase alfa at a fixed dose subcutaneously on Day 1 of each 6-week cycle for up to 18 cycles (approximately 2 years) plus calderasib until discontinuation criterion is met.","label":"Calderasib + Pembrolizumab (+) Berahyaluronidase alfa","type":"EXPERIMENTAL"},{"description":"Participants will receive pembrolizumab (+) berahyaluronidase alfa at a fixed dose subcutaneously on Day 1 of each 6-week cycle for up to 18 cycles (approximately 2 years) and pemetrexed via intravenous (IV) infusion at a dose of 500 mg/m\\^2 on days 1 and 22 of cycles 1 and 3 until discontinuation criterion is met PLUS investigator's choice of carboplatin via IV infusion at area under curve (AUC) 5 mg/mL/minute on days 1 and 22 of cycles 1 and 3 (up to 4 doses, approximately 6 weeks) OR cisplatin via IV infusion at a dose of 75 mg/m\\^2 on days 1 and 22 of cycles 1 and 3 (up to 4 doses, approximately 6 weeks).","label":"Pembrolizumab (+) Berahyaluronidase alfa + Chemotherapy","type":"ACTIVE_COMPARATOR"}],"collaborators":[],"completion_date":{"date":"2032-08-06","type":"ESTIMATED"},"conditions":["Non-small Cell Lung Cancer"],"enrollment":{"count":675,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"Calderasib","otherNames":["MK-1084"],"type":"DRUG"},{"name":"Pembrolizumab (+) Berahyaluronidase alfa","otherNames":["MK-3475A"],"type":"BIOLOGICAL"},{"name":"Pemetrexed","otherNames":["Alimta"],"type":"DRUG"},{"name":"Cisplatin","otherNames":["Platinol-AQ"],"type":"DRUG"},{"name":"Carboplatin","otherNames":["PARAPLATIN®"],"type":"DRUG"}],"last_update":"2026-10-26","lead_sponsor":"Merck Sharp & Dohme LLC","official_title":"A Phase 3, Randomized, Open-label, Multicenter Clinical Study to Evaluate the Safety and Efficacy of MK-1084 in Combination With Subcutaneous Pembrolizumab and Berahyaluronidase Alfa (MK-3475A) Versus MK-3475A in Combination With Pemetrexed/Platinum (Carboplatin or Cisplatin) Chemotherapy as First-line Treatment of Participants With KRAS G12C-Mutant, Advanced or Metastatic Nonsquamous NSCLC (KANDLELIT-007)","overall_status":"RECRUITING","phases":["PHASE3"],"primary_completion_date":{"date":"2029-12-07","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Progression Free Survival (PFS) in Participants with Programmed Death-Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥1%","timeFrame":"Up to approximately 48 months"}],"references":[],"start_date":{"date":"2025-10-08","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"A Clinical Study of Calderasib (MK-1084) and Other Treatments for Participants With Non-Small Cell Lung Cancer (MK-1084-007/KANDLELIT-007)","url":"https://clinicaltrials.gov/study/NCT07190248"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/kandlelit-007-nct07190248"}